Khorana评分在Ⅳ期胰腺癌患者中预测血栓风险的回顾性研究

A retrospective study of Khorana score prediction value to the thrombosis risk in Ⅳ stage pancreatic cancer

目的探讨Ⅳ期胰腺癌患者Khorana评分与患者血栓风险的相关性。方法回顾性分析首都医科大学附属北京友谊医院2012年1月至2017年1月收治的Ⅳ期胰腺癌患者97例,分析根据肿瘤类型、白细胞、血小板、血红蛋白、体重指数(BMI)计算的Khorana评分与血栓风险及总生存时间的关系。结果Ⅳ期胰腺癌患者普遍存在不同程度的血栓风险。Khorana评分中危组(1~2分,24例)患者发生深静脉血栓6例,占25.0%;Khorana评分高危组(评分≧3分,73例)患者发生深静脉血栓31例,占42.4%,显著高于中危组(P<0.05)。Khorana评分中危组患者的生存期为(11.92±0.27)个月,Khorana评分高危组患者的生存期为(6.88±0.17)个月,显著低于中危组(P<0.01)。结论Khorana评分可以有效预测Ⅳ期胰腺癌患者的肿瘤高凝状态,其异常升高提示患者预后较差。

Objective To examine the association of Khorana score and the thrombosis risk in Ⅳ stage pancreatic cancer. Methods Tumor types,WBC,HB,PLT,BMI of 97 Ⅳ stage pancreatic cancer patients were measured and Khorana scores were calculated. Then the relationship between Khorana scores and the thrombosis risk,overall survivals（ OS） was analyzed. Results Thrombosis risk existed in patients with Ⅳ stage pancreatic cancer. Twenty-four patients had intermediate risk and their Khorana score was 1-2,Six of them（ 25. 0%） had deep venous thrombosis. Seventy-three patients（ 73. 3%） had high risk and their Khorana score was 3 or more. Thirty-one of them（ 42. 4%） had deep venous thrombosis,and had the higher rate than intermediate risk group. The OS of intermediate risk group was（ 11. 92 ± 0. 27） month. The high risk group was（ 6. 88 ± 0. 17） month,which was significantly lower than the intermediate risk group（ P〈0. 01）. Conclusion Khorana score can reflect the thrombosis risk. It is an index of judging the prognosis of patients with stage Ⅳ pancreatic cancer,and the abnormal increase prompts poor prognosis of patients.